ARTES Biotechnology entered in development of SARS-CoV-2 vaccine Kumar Jeetendra | April 27, 2020 ARTES Biotechnology, the German-based biotech organization gaining practical experience in process improvement for recombinant immunizations, entered advancement of SARS-CoV-2 antibody applicants dependent on its infection like molecule (VLP) based stage advances METAVAX® and SplitCore. METAVAX® is the organization’s foundation for the improvement of immunizations based on wrapped infection like molecule nanostructures (eVLPs) in light of …
